Registry data compare rapamycin and leniolisib in APDS

A retrospective analysis of the ESID-APDS registry evaluated real-world use of rapamycin (81 patients) and leniolisib (28 patients) in Activated PI3K-delta syndrome, primarily for lymphoproliferation. The study reported overall response rates of 67% with rapamycin and 64% with leniolisib for lymphoproliferation, with lower response rates (35% and 50%, respectively) for other disease manifestations; treatment-limiting adverse events occurred only in the rapamycin group, and lymphoma cases were observed during follow-up. The authors state that prospective long-term studies are needed to clarify the role of these therapies and their impact on malignancy risk.

Most relevant for: Patients with Activated PI3K-delta syndrome (APDS) being managed for immune dysregulation and lymphoproliferation.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.